Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

  • Awaiting development
  • GID-TA11658
  • Expected publication date: TBC

Please note that timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2026.